期刊文献+

肝水解肽的制备及其病毒灭活/去除工艺的验证 被引量:2

Preparation of Heparolysate and Verification of Procedure for Inactivation /Removal of Virus
原文传递
导出
摘要 目的制备肝水解肽,并对其病毒灭活/去除工艺进行验证。方法以鸡新城疫病毒(NDV)和鸡传染性法氏囊病毒(IBDV)为指示病毒,在100℃,pH6.0~7.0煮沸20min灭活病毒,用截留相对分子质量为10000的中空纤维柱,在进压0.15Mpa、回流压0.05Mpa和进压0.20Mpa、回流压0.10Mpa各循环超滤3次去除病毒,用无特定病原(SPF)的鸡胚和鸡成纤维细胞进行病毒灭活/去除的效果验证。结果加热煮沸后,指示病毒未检出,滴度降低NDV≥7.4logEID50/0.2ml、IBDV≥5.45logCCID50/0.1ml;超滤后IBDV未检出,滴度降低≥5.43logCCID50/0.1ml。盲传复壮均未检出病毒。制备的肝水解肽多肽含量均在20mg/ml以上。结论制备的肝水解肽工艺中两种灭活/去除病毒方法均有效,经灭活/去除病毒后的产品质量稳定。 Objective To prepare heparolysate and verify its virus inactivation /removal procedure.Methods The Newcastle disease virusn(NDV)and infectious bursal disease virus(IBDV)as indicators were inactivated by boiling at 100℃,pH 6.0 ~ 7.0 for 20 min,then removed by ultrafiltration using hollow fiber column with a cut-off relative molecular mass of 10 000 at feeding pressure of 0.15 MPa,retention pressure of 0.05 MPa,and at feeding pressure of 0.20 MPa,retention pressure of 0.10 MPa,3 cycles for each.The virus inactivation /removal efficacies were verified by using SPF chick embryo and chick fibroblast.Results No indicator viruses were detected after boiling.The decreases of titers of NDV and IBDV were not less than 7.4 logEID50 /0.2 ml and not less than 5.45 log CCID50 /0.1 ml respectively.No IBDV was detected after ultrafiltration,and its titer decreased by not less than 5.43 logCCID50 /0.1 ml.After blind passage and recovery to normal,no virus was detected in chick embryos.The polypeptide content in prepared heparolysate was more than 20 mg /ml.Conclusion Both the procedures for virus inactivation /removal during preparation of heparolysate were effective,and the quality of obtained heparolysate was stable.
出处 《中国生物制品学杂志》 CAS CSCD 2010年第1期95-97,共3页 Chinese Journal of Biologicals
关键词 肝水解肽 病毒灭活/去除 工艺 验证 Heparolysate Virus inactivation/removal Procedure Verification
  • 相关文献

参考文献10

  • 1陶国运,张国栋.肝乐宁注射液治疗肝炎肝硬化疗效观察[J].中国误诊学杂志,2008,8(1):61-62. 被引量:6
  • 2杨国成,李汝霖,夏腊菊,汤华东,欧阳怡.超滤法去除抗乙肝转移因子中病毒工艺的验证[J].中国生化药物杂志,2004,25(6):334-335. 被引量:6
  • 3霍秀敏,罗建辉.生化药物质量控制研究中应注意的问题[J].药品评价,2005,2(2):98-101. 被引量:6
  • 4国家技术监督局.中华人民共和国新城疫检疫技术规范(GB16550-1996).1996.
  • 5国家食品药品监督管理局国家药品标准(WS1-10001-(HD-0808)-2002).2002.
  • 6Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. WHO Technical Report, Series No. 924, 2004.
  • 7国家药品监督管理局.血液制品去除/灭活病毒技术方法及验证指导原则.2002.
  • 8巩薇,付瑞,王吉,卫礼,肖镜,贺争鸣.动物源性生物制品病毒灭活/去除工艺的验证[J].中国生物制品学杂志,2007,20(12):920-923. 被引量:19
  • 9Feagins AR, Opriessnig T, Guenette DK, et al. Inactivation of infectious hepatitis E virus present in commercial pig livers sold in local grocery stores in the United States. Int J Food Microbiol, 2008, 123 (1-2): 32-37.
  • 10Kempf C, Stucki M, Boschetti N. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins. Biologicals, 2007, 35 (1): 35-42.

二级参考文献14

  • 1李振平.提高血液制品病毒安全性的途径[J].微生物学免疫学进展,1996,24(1):83-85. 被引量:1
  • 2巫协宁.临床肝胆系病学[M].上海:上海科学技术文献出版社,2002.283.
  • 3Bos O J, Sunye DG, Nieuweboer CE, et al . Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process[J]. Biologicals, 1998, 26(4):267-276.
  • 4Biesert L. Virus validation studies of immunoglobulin preparations[J]. Clin Exp Rheumatol, 1996, 14(suppl15):s47-s52.
  • 5Bellara SR, Cui Z, MacDonald SL, et al. Virus removal from bioproducts using ultrafiltration membranes modified with latex particle pretreatment [J]. Bioseparation, 1998,7(2) :79-88.
  • 6Graf EG, Jander E, West A, et al. Virus removal by filtration [J].Dev Biol Stand, 1999,99:89-94.
  • 7Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products[J]. Haemophilia,2003,9(1) :24-37 .
  • 8Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. WHO Technical Report Series. 924. 2004.
  • 9Williamson LM, Allain JP. Virally inactivated fresh frozen plasma. Vox Sang, 1995,69:159-165.
  • 10邱平,周铁群,王剑锋,李长贵,汪兴太.S/D法处理凝血因子浓缩物类制品的病毒灭活验证[J].微生物学免疫学进展,2000,28(1):44-46. 被引量:3

共引文献34

同被引文献21

  • 1杨国成,李汝霖,夏腊菊,汤华东,欧阳怡.超滤法去除抗乙肝转移因子中病毒工艺的验证[J].中国生化药物杂志,2004,25(6):334-335. 被引量:6
  • 2霍秀敏,罗建辉.生化药物质量控制研究中应注意的问题[J].药品评价,2005,2(2):98-101. 被引量:6
  • 3白春杰,杨琳,夏天瑶,崔岩,耿星海,孟多佳,丰沧玉.胸腺肽溶液不同生产方法的比较[J].中国生化药物杂志,2006,27(3):175-176. 被引量:6
  • 4国家药品审评中心.生物组织提取制品和真核细胞表达制品的病毒安全性评价技术审评一般原则[S].2005.
  • 5.消毒技术规范[S].[S].中华人民共和国卫生部,2002,11..
  • 6国家食品药品监督管理局.多组分生化药注射剂基本技术要求(试行)[S].2008.
  • 7国家食品药品监督管理局.血液制品去除/灭活病毒技术方法及验证指导原则[S].2002.
  • 8国家药品监督管理局.注射用胸腺肽国家药品标准[S].2003.
  • 9YANG S F,ZHANG H C,SHI Y X,et al.The new technologies in chitin/chitosan preparation[J].Adv Mater Res,2013,666(2):143-150.
  • 10JAYAKUMA R R,MENON D,MANZOOR K,et al.Biomedical applications of chitin and chitosan based nanomaterials-A short review[J].Carbohy Polymers,2010,82(2):227-232.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部